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Immunotherapy for Advanced Melanoma
Lei Fang1,2, Anke S. Lonsdorf1,2 and Sam T. Hwang1
Immunotherapy for melanoma has undergone significant change since the first attempts to treat patients with
high dose IL-2. Herein, strategies to boost patient antitumor immunity through vaccination, treatment with
agents that augment host immunity, and adoptive cell transfer will be discussed. The first two strategies have
yielded only limited clinical success, but adoptive cell transfer therapy, particularly following a lymphodeplet-
ing, preconditioning regimen has resulted in objective response rates approaching 50%. For a number of
reasons, lymphodepletion appears to be critical for maintenance of circulating antitumor T cells following
adoptive cell transfer. Balancing antitumor efficacy, autoimmunity, and reconstitution of a functioning immune
system remain challenging and potentially life-threatening issues.
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Introduction
Melanoma is among the most immuno-
genic of all solid cancers, as supported
by the phenomenon of spontaneous
regression of primary tumors, which
is seen in 3–15% of melanomas with
unknown primaries (Morton et al.,
1991). Moreover, the presence of tu-
mor antigen-specific antibodies and
tumor-specific cytotoxic T cells in the
peripheral blood of melanoma patients
has been well established (Lee et al.,
1999). The ability of T lymphocytes,
especially CD8 T cells, to prevent
tumor formation has been shown in
mice and humans (Shankaran et al.,
2001; Chiao and Krown, 2003), and
recent evidence indicates that the pre-
sence of infiltrating CD8 T cells within
tumors is positively correlated with
better prognosis in cutaneous melano-
ma (Ladanyi et al., 2007) as well as in
several other types of cancers (Zhang
et al., 2003). Thus, melanoma has been
of interest as an intensively studied
target for immunotherapy for over two
decades.
In general, an effective antitumor
CD8 T-cell response must fulfill a
number of criteria. First, sufficient
numbers of antitumor specific CD8
cells need to be generated in vivo
or expanded ex vivo. Second, the
CD8 T cells that are generated should
be able to traffic and infiltrate into
tumors. Finally, the CD8 T cells must
be sufficiently activated within tumors
such that they kill tumor cells, lead-
ing to tumor necrosis and/or tumor
regression. The development of murine
models of melanoma, particularly
those deploying transgenic T cells
specific for melanoma antigens, has
made it possible to better understand
mechanisms underlying effective re-
gression of established melanoma
tumors and to make adjustments
to improve immunotherapy prior to
testing new strategies in the clinic
(Finkelstein et al., 2004).
The most successful murine studies,
however, do not always translate to
safe, effective melanoma therapy for
patients. Thus, we have attempted to
list some of the most important clinical
trials involving treatment of advanced
melanoma that have been performed
in the past few years (Table 1). The
definition of clinical responses used in
this review generally refers to ‘‘objec-
tive responses’’ as defined by World
Health Organization (WHO) or WHO-
RECIST criteria (James et al., 1999).
The RECIST criteria include unidimen-
sional measures of specific tumors and/
or metastases with complete response
(CR), partial response (PR), and pro-
gressive disease responses defined by
a complete disappearance of all known
lesions (CR), at least 30% decrease
in size (PR), or 20% increase in the
size of tumors (progressive disease).
Patients who do not meet the criteria
for PR or progressive disease are
considered to have stable disease.
Although RECIST criteria allow better
comparison of clinical benefit between
various trials, some authors have ar-
gued that ‘‘stable disease’’ rather than
PR and CR may be a more realistic goal
for newer biological agents and per-
haps immunotherapy (Michaelis and
Ratain, 2006).
Currently, there are three major
approaches to boost antitumor CD8
T-cell responses in patients with mela-
noma as summarized in Figure 1: (1)
non-specific stimulation of antitumor
immune responses by stimulating endo-
genous effector cells with cytokines or
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removing inhibitory signals for T-cell
activation, (2) active immunization (that
is, vaccines) to enhance endogenous
antitumor responses in vivo, and (3)
adoptive cell-transfer (ACT) therapy as
exemplified by ex vivo selection and
expansion of autologous antitumor-
specific CD8 T cells that are subse-
quently transferred back to the patient.
This review will discuss each of these
therapeutic strategies in terms of the
preclinical studies that underlie their
mechanisms, their reported efficacy in
melanoma clinical trials, as well as their
distinct toxicity profiles.
Nonspecific stimulation of antitumor
immune responses
IFN-a and IL-2 therapy. In the 1980s,
IFN-a was reported to inhibit the
growth of B16 murine melanoma cells
in vitro and in vivo (Bart et al., 1980).
Kirkwood et al. (1996) demonstrated
for the first time that high-dose IFN-a2b
not only prolongs disease-free survival,
but also overall survival in high-risk
patients with melanomas thicker than
4 mm or with lymph node metastasis.
To date, IFN-a has been one of the
most intensely investigated immuno-
therapeutic agents for melanoma,
and it is the only currently approved
adjuvant therapy for the treatment of
high-risk melanoma patients. The effect
of IFN-a2b on disease-free survival was
confirmed in a subsequent trial, but the
study failed to prove significant effect
on overall survival (Kirkwood et al.,
2000). In an extensive meta-analysis,
investigators concluded that adjuvant
treatment with IFN-a reduces the inci-
dence of melanoma recurrence by
B26% and provides benefit in overall
survival (15% reduction in risk of death)
that is not quite statistically significant
(P¼ 0.06) (Wheatley et al., 2003). The
use of polyethylene glycol-conjugated
IFN, which has a substantially longer
half-life than the unconjugated mole-
cule, resulted in significant clinical res-
ponses of B33% when used in combi-
nation with temozolomide in patients
with advanced disease (Hwu et al.,
2006). Polyethylene glycol-conjugated
IFN may also have utility in the adjuvant
setting in melanoma patients with a
high risk of recurrence (Eggermont
et al. J Clin Oncol, 2007 ASCO Annual
Meeting Proceedings Part I. vol. 25, no.
18S (June 20 Supplement); 2007: 8504).
Considering its efficacy and ease of
administration, polyethylene glycol-
conjugated IFN is worth further investi-
gation to define its place in the treat-
ment of patients with advanced stage
melanoma.
IL-2 is known for its potent ability to
activate CD8 T cells and natural killer
cells, resulting in development of the
so-called lymphokine-activated killer
Table 1. Selected immunotherapy trials for advanced melanoma
Clinical objective response References
CTLA-4 blockade
MDX-010 monotherapy
(single dose, 3 mg kg1)
OR 0/7 Hodi et al.
(2003)
MDX-010+gp100 peptide vaccination
(3 mg kg1 every 3 weeks)
OR 3/14 (CR 2/14; PR 1/14) Phan et al.
(2003)1
MDX-010+gp100 peptide vaccination
(3 mg kg1 every 3 weeks)
OR 4/29 (CR 2/29; PR 2/29) Attia et al.
(2005)1
CP-675,206 monotherapy
(0.01–15 mg kg1, single dose)
OR 4/34 (CR 2/34; PR 2/34) Ribas et al.
(2005)
Dendritic cell-based
Peptide or tumor lysate OR 8/32 (CR 2/32; PR 6/32) Nestle et al.
(1998)
Peptide2 vs peptide+GM-CSF2 OR 1/13 (CR 0/13; PR 1/13;
SD 1/13)
OR 2/13 (CR 0/13; PR 2/13;
SD 2/13)
Slingluff
et al. (2003)1
Peptide/lysate vs DTIC OR 3/53 (CR 0/53; PR 2/53;
SD 8/53)
OR 2/55 (CR 0/55; PR 3/55;
SD 10/55)
Schadendorf
et al. (2006)1
Synthetic peptide vaccine
g209-2M (gp100-associated
antigen)+IL-2, i.v.
OR 13/31 (CR 1/31; PR 12/31) Rosenberg
et al. (1998a)
ACT
Lymphodepletion OR 6/13 (CR 0/13; PR 6/13) Dudley et al.
(2002b)
Lymphodepletion OR 18/35 (CR 3/35; PR 15/35) Dudley et al.
(2005)
Whole-cell vaccine
Canvaxins (n=150) vs no adjuvant
treatment (n=113) (resected AJCC
stage IV)
Five-year OS 39%
Five-year OS 19%
Hsueh et al.
(2002)
Melacines (n=89) vs no adjuvant
treatment (resected intermediate-
thickness AJCC stage II)
No significant difference in
OS and RFS
Sondak et al.
(2002)
Melacine+low-dose IFN-a2b vs
high-dose IFN-a2b (n=604,
resected AJCC stage III)
No significant difference in
OS and RFS
Mitchell
et al. (2007)
CR, complete response; CTLA, cytotoxic T lymphocyte antigen; i.v., intravenous; OR, objective
response; OS, overall survival; PR, partial response; RFS, recurrence-free survival; SD, stable disease.
1Clinical Response Evaluation according to RECIST.
2All patients were also administered low-dose IL-2.
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cells. Because systemic administration
of high dose of IL-2 resulted in regres-
sion of established pulmonary metas-
tases in B16 melanoma-bearing mice
(Rosenberg et al., 1985b), Rosenberg
et al. performed the first clinical trial
using autologous lymphokine-activated
killer cells and systemic IL-2 in patients
with metastatic melanoma. Although
initial clinical results were promising
(Rosenberg et al., 1985a), subsequent
trials demonstrated that high-dose
IL-2 provided consistent, but low,
overall response rate of B13–17%
(7–9% PR and 6–8% CR) (Rosenberg
et al., 1994a; Atkins et al., 1999).
Currently, IL-2 is the only FDA-
approved immunotherapeutic agent
for treatment of patients with metastatic
melanoma. Notably, within the 15
years of follow-up in these studies,
480% of the complete responders to
high-dose IL-2 treatment have not had
recurrences and may be considered
cured (personal communication, SA
Rosenberg, NCI).
The modest benefits of IL-2-based
treatment regimens, however, must be
weighed against the serious adverse
side effects and the high cost of
therapy. Moreover, recent studies have
shown that IL-2 expands CD4þCD25þ
Foxp3þ -regulatory T cells (Tregs)
in vivo, thereby possibly inducing
immune tolerance (Malek and Bayer,
2004). Furthermore, administration of
high-dose IL-2 resulted in a nearly four-
fold increase in the frequency of CD4þ
Foxp3þ Tregs in the peripheral blood
when compared with pretreatment
levels (Ahmadzadeh and Rosenberg,
2006), suggesting that Tregs may play
important downstream roles in deter-
mining responses to IL-2.
Several studies have been con-
ducted to study combinations of IL-2
and chemotherapy in advanced mela-
noma in an effort to improve res-
ponse rates and survival. Unfortu-
nately, recent phase-III trials of chemo-
therapy with high-dose IL-2 adminis-
tration resulted in increased serious
toxicity to patients and failed to
confirm significantly better durable
response rates (or overall survival)
compared with chemotherapy alone
(Rosenberg et al., 1999; Ridolfi et al.,
2002; Keilholz et al., 2005).
Anti-CTLA-4 therapy. Optimal T-cell
activation requires signaling through
both the T-cell receptor (TCR) and the
costimulatory receptor CD28, which is
constitutively expressed on T cells.
Cytotoxic T lymphocyte-associated
antigen-4 (CTLA-4), a member of
CD28 immunoglobulin family, is an
inhibitory receptor expressed mainly by
activated T cells and Tregs. CTLA-4
binds CD80 or CD86 with higher
affinity and avidity than does CD28,
thereby inhibiting CD28-dependent
T-cell activation and decreasing IL-2
production (Teft et al., 2006). The
critical negative regulatory function of
CTLA-4 was established upon charac-
terization of CTLA-4-deficient mice,
which exhibited profound lymphopro-
liferation and autoimmunity.
mAbs targeting CTLA-4 have been
shown to increase host antitumor
immunity in a number of tumor models
(Leach et al., 1996). However, anti-
CTLA4 mAb alone failed to produce
similar antitumor efficacy in a B16
melanoma model, even when the treat-
ment was initiated at the time of tumor
inoculation (van Elsas et al., 1999). By
contrast, a short course of anti-CTLA-4
blocking antibody in combination with
a GM-CSF-expressing irradiated tumor
cell vaccine eradicated established B16
melanoma in 80% of wild-type mice
and protected those mice from subse-
quent tumor challenge (van Elsas et al.,
1999). When tumors were successfully
rejected, depigmentation was observed
in 50% of the treated mice. Since
depigmentation, a marker of auto-
immunity, is an uncommon event
following vaccination alone and has
not been observed with anti-CTLA-4
monotherapy, these findings suggested
that CTLA-4 played a significant role in
breaking peripheral tolerance.
Fully humanized antibodies against
human CTLA-4, MDX-010 (ipilimu-
mab), and CP-675,206 (ticilimumab)
have been evaluated in several
published phase-I and phase-II trials
(Table 1). Anti-CTLA-4 monotherapy
has yielded response rates of 7–15% in
heavily pretreated patients with meta-
static melanoma (Korman et al., 2005;
Ribas et al., 2005). Administration of
MDX-010 in conjunction with peptide
vaccination to patients with stage-IV
melanoma resulted in objective cancer
regression in 3 of 14 patients (two CRs
and one PR) and grade-III/IV autoim-
mune manifestations in 6 of 14 patients
(43%) (Phan et al., 2003). Combination
therapy with anti-CTLA-4 and IL-2 in
patients with metastatic melanoma
yielded a similar 22% response rate
coupled with a 14% rate of grade-II/IV
autoimmune toxicities (described
below). Given an anticipated 15%
response rate to IL-2 alone in the treat-
ment of metastatic melanoma, there
does not seem to be a synergistic effect
(Maker et al., 2005).
Treatment with anti-CTLA-4 mAb
is frequently associated with adverse
immune events, most commonly invol-
ving the skin and the gastrointestinal
tract. Grade-III and grade-IV adverse
immune events, especially enterocolitis
(21%; Beck et al., 2006) and auto-
immune hypophysitis (5%; Blansfield
Cancer patient
CTLs in blood,
DLNs, and tumor
IFN-α or IL-2
Toll-like receptor agonists
Anti-CTLA-4 Ab
Boost CTL numbers and functions in vivo
Remove inhibitory signal for T cell activation in vivo
Cancer vaccines Boost CTL numbers and functions in vivo
Harvest PBMC
Engineered T cells
Harvest DLNs
Excise tumor mass
& isolate TILs
Anti-melanoma specific T cell selection
and expansion in vitro
Host preconditioning
Lymphodepleting chemotherapy
±HSC
Cancer
patient
Adoptive
transfer
IL-2
Figure 1. Strategy for immunotherapy of melanoma. CTL, cytotoxic T lymphocyte; DLN, draining lymph
node; PBMC, peripheral blood mononuclear cells; CTLA, cytotoxic T lymphocyte antigen; TIL, tumor-
infiltrating lymphocyte; HSC, hematopoietic stem cell.
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et al., 2005) have been reported. A
dermatitis characterized by pruritic
macules and papules occurred in 14%
of stage-IV melanoma patients treated
with ipilimumab as monotherapy
(Jaber et al., 2006). The erythermatous
macules and papules present in anti-
CTLA-4 dermatitis were photodistri-
buted in some patients, and a
Koebner-like phenomenon could be
elicited in others (Figure 2). Peripheral
eosinophil counts were increased by
fourfold in patients who had experi-
enced the eruption compared with in
those who had not (Jaber et al., 2006).
Of note, this pruritic skin eruption
was similar in clinical and histological
appearance (superficial perivascular
lymphocytic infiltrate with frequent
eosinophils) to the macular-papular
rash most commonly associated with
drugs such as penicillins (Jaber et al.,
2006). Autoimmune side effects have
been correlated with clinical antitumor
responses and relapse-free survival
(Attia et al., 2005), suggesting that
antitumor immunity is achieved by
blockade of CTLA-4 at the increased
risk of autoimmunity in other tissues.
Toll-like receptor agonists. Synthetic
deoxycytidyl–deoxyguanosine oligo-
deoxynucleotides contain unmethylated
CG motifs similar to those observed in
bacterial DNA. By triggering Toll-like
receptor-9 (TLR9), these oligodeoxy-
nucleotides trigger an immunostimula-
tory pathway that includes dendritic cell
(DC) activation and production of proin-
flammatory cytokines such as type-I
IFN, thus potentially favoring antitumor
immunity. In humans, only plasma-
cytoid DCs and B cells are known to
express TLR9 (Krieg, 2004).
Because TLR9 agonists have shown
efficacy in animal tumor models
(Lonsdorf et al., 2003), they are being
evaluated for their therapeutic potential
in clinical trials for melanoma patients.
The first human trial of a synthetic
deoxycytidyl–deoxyguanosine oligo-
deoxynucleotides combined with a
melanoma peptide showed that use of
CpG 7909 as an adjuvant to Melan-A/
Mart-1 peptide vaccination resulted in
10-fold increase in circulating Melan-A-
specific CD8 T cells compared with use
of peptide alone. Clinical response rates
were not obtained in this phase-I study
due to the short follow-up period
(Speiser et al., 2005).
Imiquimod, a TLR7 agonist that is
currently FDA-approved for the topical
treatment of actinic keratosis, external
genital warts, and superficial basal
cell carcinoma, also appears to hold
potential for the treatment of melano-
ma. Several cases of successful treat-
ment with topical 5% imiquimod
of otherwise untreatable cutaneous
metastases of malignant melanoma
(Steinmann et al., 2000) and melanoma
in situ (Ray et al., 2005) have been
reported. Therapeutic approaches
based on TLR agonists may be of
particular relevance in cases where
standard therapies have been refused
or are contraindicated.
Cancer vaccines
Peptide-based vaccination strategies.
The identification of defined tumor
antigens that can be the targets of
T cells has led to development of new
immunotherapeutic strategies (Boon
et al., 1997). Tumor antigens isolated
from melanomas include MART-1/
Melan-A, gp100, and tyrosinase, all of
which are melanocytic differentiation
antigens that are also expressed by
normal melanocytes. Anti-melanoma-
specific CTLs have been found in
peripheral blood, draining lymph
nodes, and within tumors in melanoma
patients (Pittet et al., 1999; Zippelius
et al., 2004). It has been suggested that
these cells may be unable to eradicate
invasive tumors due to low frequency
and/or an immunosuppressive host
microenvironment. Therefore, adminis-
tration of cancer vaccines may boost
endogenous antitumor immune res-
ponses in vivo.
Vaccines are classified as either
univalent, stimulating the immune
system against a particular antigen, or
polyvalent, eliciting immune responses
against multiple antigens. The most
extensively studied melanoma vaccines
are polyvalent whole cells or cell
lysates derived from allogenic or auto-
logous tumor cells. One advantage
of this approach is that the vaccine
immunizes the patient against a variety
of tumor antigens, without attempting
to predict which antigen will elicit the
most effective antitumor responses.
Since these vaccines are expected
to be immunogenic in patients with
various HLA types, they are poten-
tially beneficial for a larger patient
population.
Early trials of polyvalent whole-
melanoma-cell vaccines (Mitchell
et al., 1988; Morton et al., 1992; Hsueh
et al., 2002) suggested vaccines could
elicit immunological responses in mela-
noma patients and provide clinical
benefit to some patients. However,
later trials (Table 1) involving larger
numbers of patients failed to show a
clinical benefit (Sondak et al., 2002;
Faries and Morton, 2005). One poly-
valent whole-cell vaccine (Melacines)
combined with low-dose cyclophos-
phamide was shown to provide super-
ior quality of life during therapy,
a b
Figure 2. Skin dermatitis following treatment with anti-CTLA-4 mAb as a single agent as described in
Jaber et al. (2006). (a) Photodistributed macules and papules on face and neck, and (b) erythematous
papules with Koebner-like phenomenon elicited by the trauma of scratching.
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although there was no demonstrable
difference in response rates and survi-
val compared with patients treated with
a four-drug chemotherapy regimen
(Mitchell, 1998).
Immunization with melanoma-asso-
ciated peptide antigens is a strategy that
has been vigorously pursued. In one of
the first clinical trials using melanoma
cell-derived peptides, Rosenberg et al.
(1998a) vaccinated stage-IV melanoma
patients with g209-2M, a modified
immunodominant peptide of the
gp100 antigen. On the basis of immu-
nological assays, 91% of patients could
be successfully immunized with this
synthetic peptide, and 13 of 31 patients
(42%) receiving the peptide vaccine
plus IL-2 had objective cancer
responses. All patients, however, even-
tually developed progressive disease.
Nevertheless, this study provided
essential proof-of-principle of the
concept that immune responses against
self-antigens can be elicited in patients
with advanced melanoma. Although
encouraging, this and subsequent
clinical studies also highlighted the
fact that tumor progression can occur
despite induction of an antigen-specific
immune response (Powell et al., 2006).
Strategies using expression of melano-
ma peptides via recombinant adeno-
viral vectors (Rosenberg et al., 1998b)
or with plasmid vectors encoding
tumor antigen (Rosenberg et al., 2003)
were initially attractive due to their low
cost and ease of administration, but
have not resulted in clear elicitation
of immune or clinical responses in
patients. Cancer-testis antigens, expres-
sed in different tumors and normal
testis, are also potential targets for
melanoma immunotherapy. While an
initial study of the cancer-testis antigen
known as MAGE-3 resulted in tumor
regression in some patients (Marchand
et al., 1999), later studies with this
cancer-testis antigen showed poor
clinical and immunological responses
(Kruit et al., 2005).
DC-based vaccination strategies. Effec-
tive presentation of the defined tumor
antigens to the immune system of a
cancer patient remains to be one of the
most important challenges in the field.
The presentation of tumor antigen by
DCs or other antigen-presenting cells
is a central step in the induction of
an antigen-specific T-cell response, and
DCs, therefore, have been proposed to
be an ideal tool for the induction and
augmentation of an immune response
in a vaccination setting (Grabbe et al.,
1995). In recent years, the clinical use
of DCs has been facilitated by deve-
lopment of techniques to generate large
numbers of these cells in vitro from
blood monocytes or CD34þ progeni-
tor cells. The first human trial using
monocyte-derived peptide- or tumor
lysate-pulsed DCs for antigen delivery
enrolled 16 patients with advanced
melanoma and yielded five objective
responses (ORs) (2/16 CR, 3/16 PR)
(Nestle et al., 1998). Using a similar
vaccination strategy with larger num-
bers of patients, however, Schadendorf
et al. (2006) demonstrated only a 3.8%
OR rate that was similar to the OR rate
for dacarbazine. Other DC vaccination
trials have not resulted in significant
objective clinical responses, but have
shown delayed-type hypersensitivity to
the peptide antigen (Thurner et al.,
1999) or a delay in tumor progression
when patients were able to mount
immune responses to multiple anti-
gens used in the multivalent DC-based
vaccine (Banchereau et al., 2001).
Thus, although immunological respon-
ses to selected vaccination strategies
have often been detected, their clinical
utility as single agents is not promising.
In summarizing the results from 35
representative published vaccine
studies, Rosenberg et al. (2004) calcu-
lated an OR rate of 3.8% (7.1% for
DCs, 4.2% for modified tumor cells,
4.0% for peptide-based vaccines,
and 0% for pox viruses) for cancer
vaccines. Currently there are no vacci-
nation strategies that consistently
induce melanoma regression.
ACT therapy
CTL therapy. In CTL therapy, peri-
pheral blood mononuclear cells are
isolated from melanoma patients and
stimulated with autologous antigen-
presenting cells pulsed with HLA-
restricted peptide epitope of MART-1
or gp100. After several rounds of
stimulation, single clones are selected
in vitro for their abilities to specifically
kill antigen-positive tumor targets. CTL
clones are further expanded in vitro
before being adoptively transferred
back to patients (Ho et al., 2002). Early
clinical trials with CTL therapy met
with limited success as antigen-specific
CD8 T cells persisted in vivo only for
a short period of time. In addition,
recurrent tumors were found to selec-
tively lose the targeted antigen(s) (Yee
et al., 2002).
Tumor-infiltrating lymphocyte (TIL)
therapy. In contrast to cancer vaccines,
which activate the immune system
in situ, TIL therapy relies upon (1)
isolation and propagation of auto-
logous T cells present in patient tumors
(usually metastases) in the presence of
high levels of IL-2, (2) selection of
highly avid clones that produce high
levels of IFN-g against multiple mela-
noma cell lines, and (3) expansion of
those cells in vitro with anti-CD3 and
IL-2 to large numbers that are then
transferred back to the patient (Dudley
and Rosenberg, 2003).
Early attempts with TILs and high-
dose IL-2 in melanoma patients
achieved limited clinical success
(Rosenberg et al., 1994b) and were
generally characterized by poor persis-
tence of TIL clones in vivo following
adoptive transfer. Although cultured
TIL clones often showed high avidity
toward tumor-associated melanoma
peptides, only rarely were clinical
remissions achieved in excess of that
expected for IL-2 therapy alone. Thus,
high-avidity T-cell clones alone were
not sufficient for treatment efficacy.
Remarkable results in this field
were first reported by Rosenberg
et al., who used non-myeloablative,
lymphodepleting preconditioning fol-
lowed by infusion of autologous TILs
and IL-2 (Dudley et al., 2002a). Sub-
sequent studies at the NCI confirmed
response rates of B50% in advanced
melanoma patients with metastatic
disease (Dudley et al., 2005). Several
patients receiving treatment regimen
achieved impressive clinical regression
of large bulky tumors (Figure 3). The
rationale for this lymphodepleting pre-
conditioning regimen was based on
early animal studies demonstrating that
depletion of endogenous lymphocytes
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by chemotherapy (prior to adoptive
transfer of T cells) resulted in improved
antitumor responses (Cheever et al.,
1980; North, 1982; Dummer et al.,
2002). The mechanisms by which
lymphodepleting regimens improve
outcome of ACT therapy have been
shown to involve elimination of
Tregs, increasing the availability of
T-cell growth-promoting cytokines,
and improvement of the function and/
or availability of antigen-presenting
cells as discussed below (Gattinoni
et al., 2006).
Naturally occurring Tregs possess
the ability to suppress or antagonize
the function of other T cells. Tregs are
crucial for maintenance of peripheral
self-tolerance and suppression of anti-
tumor immunity (Sakaguchi, 2005).
The Tregs described in this review are
characterized by expression of the
forkhead box P3 (FoxP3) transcription
factor, CD4, and activated T-cell mar-
kers, including CD25 (IL-2 receptor-a),
glucocorticoid-induced tumor-necrosis
factor-receptor family-regulated gene,
and CTLA-4.
CD4þCD25hiFoxp3þ cells are rele-
vant to immunotherapy for melanoma
for a number of reasons. Co-transfer of
CD4þCD25þ Tregs reduced the abi-
lity of transgenic, antigen-specific CD8
T cells to induce B16 murine melano-
ma tumor regression in vivo (Antony
et al., 2005). Clinically, Foxp3þ Tregs
were overrepresented in metastatic
lymph nodes from patients with mela-
noma. Following isolation, these Tregs
inhibited proliferation and cytokine
production of tumor-infiltrating CD4
and CD8 cells in vitro (Viguier et al.,
2004). In ovarian cancer patients,
reduced survival was associated with
increased tumor-infiltrating Treg levels
(Curiel et al., 2004), whereas increased
survival was associated with a high
ratio of intratumoral CD8 T cells to
Tregs (Sato et al., 2005). Even though
the presence of Treg cells in tumor
lesions has not been conclusively con-
nected with progression of cancers, the
suppressive function of Treg cells may
contribute to poor clinical response in
non-lymphodepleting patients receiv-
ing ACT therapy.
Lymphodepleting preconditioning
regimens may also be effective because
they reduce the size of the host endo-
genous lymphocyte pool, allowing
newly transferred T cells access to
growth promoting cytokines (Goldrath
et al., 2000). Because the size of the
T-cell pool in humans and mice is
tightly maintained at a nearly constant
level, adoptive transfer of cells into a
lymphopenic host will result in rapid
expansion of the newly transferred
antigen-specific T cells in an IL-7- and
IL-15-dependent manner (Tan et al.,
2002). Dummer et al. (2002) first
reported that the antitumor benefits of
lymphodepletion were dependent on
homeostatic expansion of a polyclonal
T-cell population within lymph nodes,
indicating that T cells can be induced
to mount an effective autoimmune
response against self-antigens when
homeostatic expansion occurs at the
time of antigen encounter. In the
pmel-1 mouse model of ACT therapy
for melanoma, lymphodepletion also
enhanced antitumor efficacy of adop-
tively transferred T cells in an IL-7- and
IL-15 dependent manner (Gattinoni
et al., 2005a).
Preconditioning of the host with
systemic chemotherapy or total-body
irradiation before ACT therapy was
initially thought to result in apoptosis
or necrosis of tumor cells, allowing
more efficient presentation of tumor
antigens by host DCs to the adoptively
transferred CD8 cells. Recent results,
however, showed that total-body irra-
diation caused mucosal injury, result-
ing in microbial translocation from
gastrointestinal tract and systemic re-
lease of lipopolysaccharide. Signaling
through TLR4, lipopolysaccharide in-
creased the absolute numbers of acti-
vated DCs, which subsequently
secreted high levels of T-cell-activating
cytokines (Paulos et al., 2007).
While lymphodepletion remarkably
improves the outcome of ACT therapy,
it is not the only factor that determines
the clinical response. Preclinical and
clinical studies have implied that
the differentiation state of transferred
CD8 T cells may be crucial for the
success of ACT therapy. Upon encoun-
ter with antigen, naı¨ve CD8 T cells
proliferate and differentiate through
early, intermediate, and late effector
stages depending on signal strength
(Lanzavecchia and Sallusto, 2002).
Differentiation from early stage to late
stage of effector CD8 T cells is charac-
terized by progressive downregulation
of CD62L, CCR7, b7-integrin, and
CD27 and concurrent upregulation of
CD44, CD69, CD25, granzyme B, and
perforin. After multiple rounds of
in vitro stimulation with antigen and
IL-2, activated pmel-1-transgenic CD8
T cells acquired terminally differen-
tiated effector properties, including
increased cytolytic activity and higher
levels of IFN-g production. How-
ever, when adoptively transferred into
lymphodepleted B16 tumor-bearing
Pretreatment 16+ Months
Figure 3. Response of a melanoma tumor to a lymphodepleting chemotherapy regimen combined
with adoptive transfer of tumor-infiltrating T cells (Dudley et al., 2002a). (photo courtesy of
Dr Steven A. Rosenberg, Surgery Branch, NCI).
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wild-type mice, terminally differen-
tiated pmel-1 CD8 T cells were at least
100-fold less effective than early effec-
tor CD8 cells in antitumor efficacy
(Gattinoni et al., 2005b). In addition,
terminally differentiated pmel-1 CD8
T cells proliferated poorly in vivo,
suggesting they might have already
exhausted their abilities to proliferate
and to persist in vivo once adoptively
transferred. On the other hand, early
effector CD8 T cells possessing essen-
tial adhesion molecules for trafficking
to lymph nodes showed superior anti-
tumor efficacy compared with T cells
that could not traffic to lymph nodes
(Gattinoni et al., 2005b). These findings
suggest that trafficking of less differen-
tiated CD8 T cells to lymph nodes
(where they can be effectively stimu-
lated by DCs) may be more effective in
ACT for cancer.
These findings pose new challenges
for ACT-based immunotherapy. Cur-
rently, the only criteria clinically used
to screen for TIL clones is their ability to
produce high levels of IFN-g and to kill
antigen-specific target cells in vitro.
Selected TIL clones undergo several
rounds of expansion with anti-CD3,
IL-2, and allogeneic antigen-presenting
cells, which inevitably led to selection
of late-stage or terminal differentiated
TIL clones for adoptive transfer. Two
ACT clinical studies using tumor-
reactive CD8 T cells generated and
expanded ex vivo through multiple
stimulations did not show substantial
ORs, although transferred CD8 cells
showed potent antitumor activity
in vitro (Dudley et al., 2002b; Yee
et al., 2002). Thus, balancing the
quality and quantity of the transferred
cells poses one of the greatest chal-
lenges for ACT therapy.
While lymphodepletion combined
with ACT shows great promise, lym-
phodepletion appears to increase the
risk of viral infections and virus-
associated cancers, perhaps because
of the long period of time required for
lymphocyte recovery following chemo-
therapy (Dudley et al., 2002b). Further-
more, use of high-dose IL-2 following
transfer of T cells exposes patients to
many of the same risks incurred by IL-2
therapy in the past. The use of gene-
tically engineered T cells that endo-
genously express IL-2 may remove the
need to give patients high systemic
doses of IL-2 (see below). Alternatively,
modifications of IL-2 that result in more
T-cell (vs natural killer cell) selectivity
may reduce systemic toxicity (Shanafelt
et al., 2000). Clearly, advances in
reducing the use of systemic IL-2 (or
replacing it with less toxic alternatives)
would make ACT a more attractive
(and safer) therapy for melanoma.
Additional strategies for improving
immunotherapy for melanoma
Engineered T-cell therapy. Although
ACT therapy has achieved objective
tumor regression in patients with meta-
static melanoma, not all the biopsy
specimens yield high-avidity TIL clones
for adoptive transfer (Dudley et al.,
2003). One approach to overcome this
limitation is to generate and adoptively
transfer engineered autologous T cells
that express cloned high-affinity TCRs
for melanoma-specific antigens. TILs
recognize tumor-associated antigens
through major histocompatibility com-
plex-restricted TCRs that are composed
of TCR-a and -b chains. Rosenberg
et al. have identified individual patient
TIL clones showing high affinity in vitro
to specific melanoma antigens (for
example, gp100); they cloned the
TCR-a and -b chains from these TILs
and subsequently expressed these
TCRs using retroviruses in peripheral
blood T cells from other patients
(Morgan et al., 2003). The genetically
engineered T cells secreted high
levels of IFN-g and were cytolytic
against both melanoma cell lines and
autologous melanoma cells. Impor-
tantly, following adoptive transfer into
melanoma patients lymphodepleted
by chemotherapy, transduced T cells
expressing the cloned TCR chains
persisted at high levels in the peripheral
blood for at least 2 months (and up to
1 year) in patients (Morgan et al., 2006).
Although clinical response rate in
this study was lower than that achieved
using autologous TILs (Dudley et al.,
2005), several approaches to increase
efficiency of TCR expression may
potentially enhance clinical efficacy
(Cohen et al., 2007; Zhao et al.,
2007). Furthermore, transducing tumor-
reactive T cells with IL-2 (Liu and
Rosenberg, 2001) or IL-15 (Klebanoff
et al., 2004) may promote survival of
TILs without subjecting patients to the
toxicities of systemically administered
IL-2.
Potential synergy of immunotherapy
and blockade of chemokine receptor-
mediated survival pathways
Clinical studies showed that selected
chemokine receptors, particularly
CXCR4, are often upregulated in a
large number of common human
cancers, including melanoma, and
that chemokine receptors (in concert
with their chemokine ligands) facilitate
cancer survival and metastasis through
a number of mechanisms (Muller
et al., 2001; Murakami et al., 2002;
Kakinuma and Hwang, 2006). The
CXCR4 ligand, CXCL12, protected B16
cells from killing by activated pmel-1
CD8 T cells in vitro (Lee et al., 2006),
presumably through activation of
the phosphoinositide-3-kinase and its
downstream effector, Akt (Murakami
et al., 2003). Inhibition of CXCR4 by a
peptide antagonist, T22, in combination
with cyclophosphamide or anti-
CTLA-4 antibody significantly reduced
metastatic tumor burden in the lungs
compared with treatment with cyclo-
phosphamide or anti-CTLA-4 alone (Lee
et al., 2006). This study suggests that
pretreatment of patients with a chemo-
kine-receptor antagonist prior to immu-
notherapy may result in better clinical
responses.
Summary
Until recently, immunotherapy for
melanoma has made only small incre-
mental improvements since the first
attempts to treat patients with high-
dose IL-2. Vaccination strategies alone
have shown little efficacy, whereas
attempts to boost the endogenous host
antitumor response with agents such as
anti-CTLA4 have met with marginal
success. In the case of the latter agent,
clinical efficacy in shrinking tumors has
often come at a high price in terms of
autoimmune toxicities that have been
potentially life threatening. By contrast,
ACT therapy, particularly following
lymphodepleting, preconditioning regi-
men has resulted in response rates
approaching 50%. Lymphodepletion
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appears to be particularly critical for
the success of these therapies because
(1) it provides access to cytokines that
promote growth and survival of newly
transferred T cells and (2) it removes
suppressive or regulatory T-cell popu-
lations.
Developing safe lymphodepleting
regimens will be a challenge, since
toxicities of high-dose IL-2 and delays
in immune reconstitution remain major
impediments to ACT. Future enhance-
ments to ACT include using total-
body irradiation to activate antigen-
presenting cells via TLRs (in addition
to reducing endogenous T-cell popula-
tions through bone marrow suppres-
sion). These experiments suggest that
the growing library of clinical-grade
TLR agonists may prove to be valuable
adjuvants for ACT. Lastly, genetic
manipulation of either allogeneic or
autologous T cells with highly avid
cloned TCRs selected for clinical effi-
cacy or with cloned cytokines such
as IL-2 and IL-15 may allow production
of highly tumor-reactive T cells that
can be delivered far more quickly and
with less cost than the current methods
of culturing tumor-infiltrating T cells
from resected tumors. While prognosis
for the majority of patients with ad-
vanced metastatic melanoma remains
relatively poor, almost half of the
patients with advanced melanoma can
obtain substantial ORs using current
ACT regimens. Improvements to cur-
rent treatment strategies that are now
being refined in mouse models of
melanoma suggest that future enhance-
ments in clinical efficacy are forth-
coming.
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